

Empowering Innovators.
Unlocking Nature's Potential.

Enabling genome editing to be a truly empowering technology

Uncertainty around the CRISPR intellectual property landscape presents a barrier to entry for innovators wishing to utilize genome editing for the advancement of their research and commercial goals. Benson Hill's CRISPR Cms1 portfolio together with a unique partnership model offer an alternative genome editing solution for those interested in accessing this powerful tool to accelerate innovation in their organizations.

Benson Hill's patented portfolio of the CRISPR Cms1 family represents a major expansion of the genome editing toolbox that is currently available to researchers. Specifically, CRISPR Cms1 nucleases are smaller than most CRISPR Cas9 and Cpf1 nucleases and have a simple RNA structure, significantly streamlining delivery of core genome editing reagents. The efficacy of this nuclease family in vivo is substantial and suggests translatability across target systems. Benson Hill aims to empower innovators with clear intellectual property rights and a licensing model that is transparent and simple. In the past year we've licensed our Cms1 nucleases in wide range of applications and fields, ranging from microbial applications to crops such as soybeans, wheat and rice.

We invite you to be part of a community of innovators and partner with us to leverage these powerful tools in your field of interest.

Nuclease	Type	in planta activity	Microbial activity	Mammalian Cells	in vitro activity	IP Status
Sm	Cms1	Yes	Yes	In Progress	In Progress	Issued Patent
Su	Cms1	Yes	In Progress	In Progress	In Progress	Issued Patent
Ob	Cms1	Yes	In Progress	In Progress	In Progress	Issued Patent
Mi	Cms1	Yes	In Progress	In Progress	In Progress	Issued Patent